Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilent Technologies Inc (A) vs TransMedics Group Inc (TMDX) Price & Performance

Agilent Technologies IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Agilent Technologies Inc vs TransMedics Group Inc — how do they compare? Agilent Technologies Inc trades at $149.49 (market cap $42.22B), while TransMedics Group Inc trades at $89.4 (market cap $3.10B). The key difference: Agilent Technologies Inc is far larger — about 13.6× TransMedics Group Inc's market cap, and Agilent Technologies Inc pays a 0.68% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

ATMDX
Market Cap
$42.22B$3.10B
Sector
HealthTechnology
52-Week High
$157.20$150.42
52-Week Low
$110.24$61.99
Enterprise Value
$43.77B$3.49B
Dividend Yield
0.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilent Technologies Inc

Agilent Technologies (A) trades at $148.72, up 1.88% with strong analyst support (77.5% buy ratings). The stock shows bullish technical momentum above key support levels, supported by consistent revenue around $6.9B and robust profitability with 19.55% net margins. Recent FDA approvals for diagnostic tests and the Biocare Medical acquisition enhance growth prospects in biopharma markets.

Outlook remains positive with a $154.90 consensus price target offering 4% upside, though high P/E of 30.02 poses valuation risk. Key catalysts include Q2 2026 earnings due August 26 and AI-driven lab expansion, while overbought RSI levels near 92 suggest near-term consolidation potential.

TransMedics Group Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Agilent Technologies Inc

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.

Read more on A

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX